focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

Mon, 18th Dec 2023 07:55

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Last week saw a rally in stock markets across the globe, thanks to a dovish pivot from the US Federal Reserve, though the FTSE 100 underperformed somewhat. This week, investors will be keeping a close eye on Friday's US personal consumption expenditures price index data - the Fed's preferred metric of inflation.

Another key focal point for the week will be the Bank of Japan's monetary policy decision to be announced on Tuesday.

"There is nothing more than a slim probability for the BoJ to exit negative rates this week, but investors are eager to hear further details about how and when the BoJ will leave the negative rate territory," said Swissquote Bank senior analyst Ipek Ozkardeskaya.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 10.4 points, 0.1%, at 7,561.96

----------

Hang Seng: down 1.1% at 16,612.95

Nikkei 225: closed up 0.6% at 32,758.98

S&P/ASX 200: closed down 0.2% at 7,426.40

----------

DJIA: closed up 0.2%, at 37,305.16

S&P 500: closed little changed at 4,719.19

Nasdaq Composite: closed up 0.4% at 14,813.92

----------

EUR: up at USD1.0919 (USD1.0912)

GBP: down at USD1.2689 (USD1.2693)

USD: up at JPY142.26 (JPY141.75)

GOLD: down at USD2,023.33 per ounce (USD2,034.62)

OIL (Brent): up at USD77.31 a barrel (USD76.34)

(changes since previous London equities close)

----------

ECONOMICS

----------

Monday's key economic events still to come:

10:00 CET Germany Ifo business climate index

09:30 GMT UK card spending statistics

10:00 EST US NAHB housing market index

----------

BROKER RATING CHANGES

----------

Morgan Stanley cuts Fresnillo to 'underweight' (equal-weight) - price target to 540 (620) pence

----------

UBS cuts Barratt Developments to 'neutral' (buy) - price target 610 (495) pence

----------

UBS raises Taylor Wimpey to 'buy' (neutral) - price target 160 (126) pence

----------

COMPANIES - FTSE 100

----------

Spirax-Sarco Engineering named Louisa Burdett as its new chief financial officer, with a starting date of July next year. Burdett is currently CFO at Croda International, and has led finance functions at "several large companies" including Meggitt and Victrex. Spirax-Sarco said CFO Nimesh Patel, who was previously announced to be its new CEO, will take the helm of the firm on January 16. Group finance director, Phil Scott, will be interim CFO from that date until Burdett joins the company. Croda International noted Burdett's departure, and said it has begun the search for her successor. Additionally, Croda said adjusted pretax profit was likely to come at the lower end of its guidance of GBP300 million to GBP320 million range, mostly due to recent currency movements, especially in Argentina.

----------

GSK announced positive headline results from the second part of its phase III trial of Jemperli plus standard-of-care chemotherapy, followed by dostarlimab plus Zejula as maintenance therapy, in adult patients with primary advanced or recurrent endometrial cancer. "The trial, which evaluated this combination against placebo plus chemotherapy followed by placebo, met its primary endpoint of progression-free survival, with a statistically significant and clinically meaningful benefit observed in both the overall patient population and in a subpopulation of patients with mismatch repair proficient/microsatellite stable tumours," GSK explained.

----------

The Financial Times reported that GSK is looking for some new deals in China. This comes after GSK rebuilt a "very strong" relationship with the government and local companies since a corruption scandal a decade ago, the newspaper said. Chief Commercial Officer Luke Miels told the FT that GSK is working on further deals with Chinese companies after it signed a licensing agreement in October worth up to USD1.5 billion for a cancer drug developed by Hansoh Pharmaceutical Group.

----------

Frasers Group is in talks to buy Matchesfashion, a luxury clothing retailer, from its private equity owner since 2017, Apax Partners, Sky News reported on Saturday. Citing "City sources", Sky said Frasers is among a small group of bidders that submitted offers early last week. Frasers would likely pay in excess of GBP50 million for Matchesfashion, whose business has struggled, according to Sky, citing an "insider". Sky said fellow London-listed retailer Next also is said to have expressed an interest in buying Matchesfashion.

----------

COMPANIES - FTSE 250

----------

Games Workshop has entered an agreement with Amazon's Content Services subsidiary for the prospective development of its Warhammer 40,000 universe into films and television series, alongside the associated merchandising rights. The deal grants exclusive rights to Amazon for film and TV series set within the universe, as well as an option for exclusive rights in the Warhammer Fantasy universe down the line. "Games Workshop and Amazon will work together for a period of 12 months to agree creative guidelines for the films and television series to be developed by Amazon. The agreement will only proceed once the creative guidelines are mutually agreed between Games Workshop and Amazon," the UK company said. It added that it will make no change to its forecast for its financial year ending in June. Games Workshop had announce an agreement in principle with Amazon in December last year.

----------

IP Group has launched a share buy back for up to GBP20 million. The intellectual property investor said the programme came in light of the discount of its share price to its net asset value per share, and it determined now to be "an appropriate time".

----------

OTHER COMPANIES

----------

Hollywood Bowl held its annual dividend unchanged and announced plans for a share buyback worth up to GBP10 million. The operator of ten-pin bowling centres reported pretax profit of GBP45.1 million for the financial year that ended September 30, down from GBP46.7 million in financial 2022, which benefited from a reduced rate of value-added tax on bowling.

----------

Canadian Overseas Petroleum said its non-binding Cole Creek joint venture letter of intent has been terminated, and it plans "no further discussions at this stage". Back in July, COPL had announced the potential joint venture with "an established energy company" to develop and exploit oil reserves at the Cole Creek in Converse and Natrona counties, Wyoming. "The company will provide a further update before year end regarding its strategy relating to the development of its Cole Creek and Barron Flats Shannon Units," COPL said on Monday.

----------

By Elizabeth Winter, Alliance News deputy news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.